SCHEMBL137922

SCHEMBL137922

[CH]1Cc2cccc3c2C1CCC3

nearest known ligand 0.52

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.36
IDO1 P14902 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10684858 0.81 ATM (0.47) TSHRIDO1
SCHEMBL829452 0.72 TSHR (0.43) TSHR
SCHEMBL718791 0.68 TSHR (0.40) TSHR
SCHEMBL30739530 0.68 TSHR (0.40) TSHR
SCHEMBL5527062 0.68 MAPT (0.33) TSHRIDO1
SCHEMBL10748012 0.68 ATM (0.49)
Ammonia Solution, Strong SCHEMBL8699361 0.67 GID4 (0.45) IDO1
SCHEMBL829845 0.66 TSHR (0.48) TSHR
SCHEMBL14301431 0.63 PRCP (0.39) TSHR
SCHEMBL137923 0.63 TSHR (0.34) TSHRIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 US disclosed
US-20230128889-A1 REL/RELA/SPOT SMALL MOLECULES MODULATORS AND SCREENING METHODS Université Libre de Bruxelles (BE) 2023-04-27 US disclosed
EP-4128250-A1 REL/RELA/SPOT SMALL MOLECULES MODULATORS AND SCREENING METHODS Université Libre de Bruxelles (BE) 2023-02-08 EP disclosed
US-11566025-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-01-31 US disclosed
US-20220403103-A1 Process for Polymerising Lactide Using a Liquid Catalyst Formulation TOTALENERGIES CORBION B.V. (NL) 2022-12-22 US disclosed
WO-2021197574-A1 REL/RELA/SPOT SMALL MOLECULES MODULATORS AND SCREENING METHODS Université Libre de Bruxelles (BE) 2021-10-07 WO disclosed
US-20200253934-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2020-08-13 US disclosed
EP-2978753-B1 NOVEL VIRAL REPLICATION INHIBITORS UNIV LEUVEN KATH (BE) 2020-08-12 EP disclosed
US-20200223845-A1 NOVEL VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2020-07-16 US disclosed
US-10633378-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2020-04-28 US disclosed
US-20140213586-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2014-07-31 US disclosed
US-8785638-B2 Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2014-07-22 US disclosed
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2014-03-06 US disclosed
US-8618138-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2013-12-31 US disclosed
US-20130289033-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2013-10-31 US disclosed
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2013-10-17 US disclosed
US-20130245049-A1 Novel Antiviral Compounds KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2013-09-19 US disclosed
US-20120129840-A1 NOVEL VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2012-05-24 US disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed
US-20120059028-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN TSHR 4264/4885IDO1 9/4885
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, PSEN1 TSHR 3043/4885IDO1 3009/4885
US-20120129840-A1 NOVEL VIRAL REPLICATION INHIBITORS MAVS, EIF2AK2, SAMHD1 TSHR 4877/4885IDO1 508/4885
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN TSHR 4280/4885IDO1 9/4885
US-11566025-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 TSHR 4827/4885IDO1 1857/4885
US-20130289033-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, PSEN1 TSHR 2843/4885IDO1 3032/4885
US-20140213586-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 TSHR 4827/4885IDO1 1857/4885
US-10633378-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 TSHR 4827/4885IDO1 1857/4885
US-20130245049-A1 Novel Antiviral Compounds MAVS, EIF2AK2, ZC3HAV1 TSHR 4876/4885IDO1 135/4885
US-20120059028-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS TYMP, DUT, MAVS TSHR 4614/4885IDO1 65/4885
US-20200253934-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS PDE4A, PDE12, PDE2A TSHR 4315/4885IDO1 3319/4885
US-20200223845-A1 NOVEL VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, IRF3 TSHR 4803/4885IDO1 2408/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 TSHR 4827/4885IDO1 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.